Development of COVID-19 vaccine using a dual Toll-like receptor ligand liposome adjuvant

We developed a SARS-CoV-2 spike subunit vaccine formulation containing dual TLR ligand liposome adjuvant. The vaccine-induced robust systemic neutralizing antibodies and completely protected mice from a lethal challenge. Two immunizations protected against lung injury and cleared the virus from lung...

Descripción completa

Detalles Bibliográficos
Autores principales: Abhyankar, Mayuresh M., Mann, Barbara J., Sturek, Jeffrey M., Brovero, Savannah, Moreau, G. Brett, Sengar, Anjali, Richardson, Crystal M., Agah, Sayeh, Pomés, Anna, Kasson, Peter M., Tomai, Mark A., Fox, Christopher B., Petri, William A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8602664/
https://www.ncbi.nlm.nih.gov/pubmed/34795290
http://dx.doi.org/10.1038/s41541-021-00399-0
_version_ 1784601617702584320
author Abhyankar, Mayuresh M.
Mann, Barbara J.
Sturek, Jeffrey M.
Brovero, Savannah
Moreau, G. Brett
Sengar, Anjali
Richardson, Crystal M.
Agah, Sayeh
Pomés, Anna
Kasson, Peter M.
Tomai, Mark A.
Fox, Christopher B.
Petri, William A.
author_facet Abhyankar, Mayuresh M.
Mann, Barbara J.
Sturek, Jeffrey M.
Brovero, Savannah
Moreau, G. Brett
Sengar, Anjali
Richardson, Crystal M.
Agah, Sayeh
Pomés, Anna
Kasson, Peter M.
Tomai, Mark A.
Fox, Christopher B.
Petri, William A.
author_sort Abhyankar, Mayuresh M.
collection PubMed
description We developed a SARS-CoV-2 spike subunit vaccine formulation containing dual TLR ligand liposome adjuvant. The vaccine-induced robust systemic neutralizing antibodies and completely protected mice from a lethal challenge. Two immunizations protected against lung injury and cleared the virus from lungs upon challenge. The adjuvanted vaccine also elicited systemic and local anti-Spike IgA which can be an important feature for a COVID-19 vaccine.
format Online
Article
Text
id pubmed-8602664
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-86026642021-12-03 Development of COVID-19 vaccine using a dual Toll-like receptor ligand liposome adjuvant Abhyankar, Mayuresh M. Mann, Barbara J. Sturek, Jeffrey M. Brovero, Savannah Moreau, G. Brett Sengar, Anjali Richardson, Crystal M. Agah, Sayeh Pomés, Anna Kasson, Peter M. Tomai, Mark A. Fox, Christopher B. Petri, William A. NPJ Vaccines Brief Communication We developed a SARS-CoV-2 spike subunit vaccine formulation containing dual TLR ligand liposome adjuvant. The vaccine-induced robust systemic neutralizing antibodies and completely protected mice from a lethal challenge. Two immunizations protected against lung injury and cleared the virus from lungs upon challenge. The adjuvanted vaccine also elicited systemic and local anti-Spike IgA which can be an important feature for a COVID-19 vaccine. Nature Publishing Group UK 2021-11-18 /pmc/articles/PMC8602664/ /pubmed/34795290 http://dx.doi.org/10.1038/s41541-021-00399-0 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Brief Communication
Abhyankar, Mayuresh M.
Mann, Barbara J.
Sturek, Jeffrey M.
Brovero, Savannah
Moreau, G. Brett
Sengar, Anjali
Richardson, Crystal M.
Agah, Sayeh
Pomés, Anna
Kasson, Peter M.
Tomai, Mark A.
Fox, Christopher B.
Petri, William A.
Development of COVID-19 vaccine using a dual Toll-like receptor ligand liposome adjuvant
title Development of COVID-19 vaccine using a dual Toll-like receptor ligand liposome adjuvant
title_full Development of COVID-19 vaccine using a dual Toll-like receptor ligand liposome adjuvant
title_fullStr Development of COVID-19 vaccine using a dual Toll-like receptor ligand liposome adjuvant
title_full_unstemmed Development of COVID-19 vaccine using a dual Toll-like receptor ligand liposome adjuvant
title_short Development of COVID-19 vaccine using a dual Toll-like receptor ligand liposome adjuvant
title_sort development of covid-19 vaccine using a dual toll-like receptor ligand liposome adjuvant
topic Brief Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8602664/
https://www.ncbi.nlm.nih.gov/pubmed/34795290
http://dx.doi.org/10.1038/s41541-021-00399-0
work_keys_str_mv AT abhyankarmayureshm developmentofcovid19vaccineusingadualtolllikereceptorligandliposomeadjuvant
AT mannbarbaraj developmentofcovid19vaccineusingadualtolllikereceptorligandliposomeadjuvant
AT sturekjeffreym developmentofcovid19vaccineusingadualtolllikereceptorligandliposomeadjuvant
AT broverosavannah developmentofcovid19vaccineusingadualtolllikereceptorligandliposomeadjuvant
AT moreaugbrett developmentofcovid19vaccineusingadualtolllikereceptorligandliposomeadjuvant
AT sengaranjali developmentofcovid19vaccineusingadualtolllikereceptorligandliposomeadjuvant
AT richardsoncrystalm developmentofcovid19vaccineusingadualtolllikereceptorligandliposomeadjuvant
AT agahsayeh developmentofcovid19vaccineusingadualtolllikereceptorligandliposomeadjuvant
AT pomesanna developmentofcovid19vaccineusingadualtolllikereceptorligandliposomeadjuvant
AT kassonpeterm developmentofcovid19vaccineusingadualtolllikereceptorligandliposomeadjuvant
AT tomaimarka developmentofcovid19vaccineusingadualtolllikereceptorligandliposomeadjuvant
AT foxchristopherb developmentofcovid19vaccineusingadualtolllikereceptorligandliposomeadjuvant
AT petriwilliama developmentofcovid19vaccineusingadualtolllikereceptorligandliposomeadjuvant

Ejemplares similares